Compounds > kanamycin a
Page last updated: 2024-08-17

kanamycin a and Disease Exacerbation

kanamycin a has been researched along with Disease Exacerbation in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's1 (25.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Higuchi, M; Kanai, N; Kawai, K; Kayasaki, F; Kondo, H; Kondo, N; Mukai, T; Sasaki, Y; Sawaguchi, N; Shinozuka, Y; Sugimoto, K; Takeda, A; Watanabe, A; Yamada, M; Yasuda, A1
Bang, H; Barry, CE; Dartois, V; Eum, S; Fox, WS; Gupta, SV; Lee, M; Savic, RM; Shim, T; Strydom, N; Via, LE; Zimmerman, M1
Harada, H; Kita, E; Kurioka, T; Yunou, Y1
Baranov, E; Hoffman, RM; Moossa, AR; Penman, S; Wang, X; Yang, M; Zhao, M1

Trials

1 trial(s) available for kanamycin a and Disease Exacerbation

ArticleYear
Randomized clinical trial to evaluate the effectiveness of enrofloxacin as a second-line antibiotic for treatment of acute Escherichia coli mastitis.
    Animal science journal = Nihon chikusan Gakkaiho, 2018, Volume: 89, Issue:7

    Topics: Acute Disease; Animals; Anti-Bacterial Agents; Appetite; Cattle; Cattle Diseases; Disease Progression; Drug Therapy, Combination; Enrofloxacin; Escherichia coli Infections; Female; Fluoroquinolones; Kanamycin; Mastitis; Oxytetracycline; Retreatment; Time Factors; Treatment Failure; Treatment Outcome

2018

Other Studies

3 other study(ies) available for kanamycin a and Disease Exacerbation

ArticleYear
Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization.
    PLoS medicine, 2019, Volume: 16, Issue:4

    Topics: Adult; Antitubercular Agents; Decision Support Techniques; Disease Progression; Drug Administration Schedule; Drug Dosage Calculations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Isoniazid; Kanamycin; Linezolid; Lung; Male; Middle Aged; Pyrazinamide; Retrospective Studies; Rifampin; Tissue Distribution; Treatment Failure; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult

2019
Efficacy of antibiotic therapy for infection with Shiga-like toxin-producing Escherichia coli O157:H7 in mice with protein-calorie malnutrition.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1999, Volume: 18, Issue:8

    Topics: Ampicillin; Animals; Anti-Bacterial Agents; Bacterial Toxins; Brain Chemistry; Disease Models, Animal; Disease Progression; Escherichia coli Infections; Escherichia coli O157; Feces; Fosfomycin; Kanamycin; Mice; Mice, Inbred C57BL; Norfloxacin; Protein-Energy Malnutrition; Reference Values; Sensitivity and Specificity; Shiga Toxins; Statistics, Nonparametric; Survival Rate; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination

1999
Spatial-temporal imaging of bacterial infection and antibiotic response in intact animals.
    Proceedings of the National Academy of Sciences of the United States of America, 2001, Aug-14, Volume: 98, Issue:17

    Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Colitis; Computer Systems; Digestive System; Disease Progression; Enteritis; Escherichia coli; Escherichia coli Infections; Female; Fiber Optic Technology; Fluorescent Dyes; Fluorometry; Gastritis; Green Fluorescent Proteins; Image Processing, Computer-Assisted; Injections, Intraperitoneal; Kanamycin; Lighting; Luminescent Proteins; Mice; Mice, Nude; Peritonitis; Videotape Recording

2001